FCGR3A and neoplasm: Similarly, the probability of success of anti-CTLA-4 treatment ipilimumab in melanoma patients increases when high-affinity polymorphisms in CD16 (V158F) are present, suggesting that NK cells and monocytes bearing this receptor are involved in the depletion of suppressive Tregs at the tumor site [40].